MOR - CTI BioPharma Corp.: Pacritinib Approval Downgrade To A Sell Rating
- FDA approved Pacritinib on Feb 28th, and the stock has appreciated more than 150%. However, the risk-reward has deteriorated significantly since our last article.
- The company does not have any more short-term catalysts, and considering that Pacritinib is an encumbered asset (deal with DRI), we do not think M&A is a likely scenario.
- We are downgrading to a sell as we expect selling pressure to abound from fund managers trying to short the launch.
- Commercialization remains to be uncertain, and dilution may be a potential risk.
For further details see:
CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating